These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25899363)

  • 1. [Equitable access to medication].
    Leiten EO; Vikan IM; Vik A; Årstøl E
    Tidsskr Nor Laegeforen; 2015 Apr; 135(7):634. PubMed ID: 25899363
    [No Abstract]   [Full Text] [Related]  

  • 2. More drugs, less protection.
    Nature; 2002 Sep; 419(6904):233. PubMed ID: 12239521
    [No Abstract]   [Full Text] [Related]  

  • 3. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 4. Questions raised about whether compulsory licenses get best prices.
    Owens B
    Nat Med; 2015 Apr; 21(4):300. PubMed ID: 25849264
    [No Abstract]   [Full Text] [Related]  

  • 5. The Health Impact Fund: incentives for improving access to medicines.
    Banerjee A; Hollis A; Pogge T
    Lancet; 2010 Jan; 375(9709):166-9. PubMed ID: 20109894
    [No Abstract]   [Full Text] [Related]  

  • 6. India: access to affordable drugs and the right to health.
    Grover A; Citro B
    Lancet; 2011 Mar; 377(9770):976-7. PubMed ID: 21227487
    [No Abstract]   [Full Text] [Related]  

  • 7. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
    Berger JM
    Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
    [No Abstract]   [Full Text] [Related]  

  • 8. The missing ingredient in medicine patent pools.
    Gold ER; Morin JF
    Lancet; 2009 Oct; 374(9698):1329-30. PubMed ID: 19837251
    [No Abstract]   [Full Text] [Related]  

  • 9. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
    Ghosh S
    Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
    [No Abstract]   [Full Text] [Related]  

  • 10. The people vs patents.
    New Sci; 2002 Jul; 175(2351):3. PubMed ID: 12625337
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 12. Compulsory licensure: the case of Cipro and beyond.
    Chakrabarty AM
    Am J Bioeth; 2002; 2(3):40. PubMed ID: 12230853
    [No Abstract]   [Full Text] [Related]  

  • 13. Universities struggle to make patents pay.
    Ledford H
    Nature; 2013 Sep; 501(7468):471-2. PubMed ID: 24067689
    [No Abstract]   [Full Text] [Related]  

  • 14. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
    Schuklenk U
    Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
    [No Abstract]   [Full Text] [Related]  

  • 15. Intellectual property rights, the World Trade Organization and public health: the Brazilian perspective.
    Viana JM
    Conn J Int Law; 2002; 17(2):311-8. PubMed ID: 12688298
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug prices and trends before and after requesting compulsory licenses: the Ecuadorian experience.
    Ortiz-Prado E; Cevallos-Sierra G; Teran E; Vasconez E; Borrero-Maldonado D; Ponce Zea J; Simbaña-Rivera K; Gómez-Barreno L
    Expert Opin Ther Pat; 2019 Aug; 29(8):653-662. PubMed ID: 31298053
    [No Abstract]   [Full Text] [Related]  

  • 17. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
    Sykes AO
    Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
    [No Abstract]   [Full Text] [Related]  

  • 18. Goodbye Columbus! New NRDOs forego discovery.
    Thiel KA
    Nat Biotechnol; 2004 Sep; 22(9):1087-92. PubMed ID: 15340473
    [No Abstract]   [Full Text] [Related]  

  • 19. Patents or patients? Global access to pharmaceuticals and social justice.
    de Wildt G; Khoon CC
    Med Confl Surviv; 2008; 24 Suppl 1():S52-61. PubMed ID: 18771195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
    Gillat A
    Food Drug Law J; 2003; 58(4):711-40. PubMed ID: 15027457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.